216 related articles for article (PubMed ID: 28926422)
1. Two faces of Hippo: activate or suppress the Hippo pathway in cancer.
Cao J; Huang W
Anticancer Drugs; 2017 Nov; 28(10):1079-1085. PubMed ID: 28926422
[TBL] [Abstract][Full Text] [Related]
2. Hippo-YAP signaling pathway: A new paradigm for cancer therapy.
Ma Y; Yang Y; Wang F; Wei Q; Qin H
Int J Cancer; 2015 Nov; 137(10):2275-86. PubMed ID: 25042563
[TBL] [Abstract][Full Text] [Related]
3. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.
Santucci M; Vignudelli T; Ferrari S; Mor M; Scalvini L; Bolognesi ML; Uliassi E; Costi MP
J Med Chem; 2015 Jun; 58(12):4857-73. PubMed ID: 25719868
[TBL] [Abstract][Full Text] [Related]
4. Furry protein suppresses nuclear localization of yes-associated protein (YAP) by activating NDR kinase and binding to YAP.
Irie K; Nagai T; Mizuno K
J Biol Chem; 2020 Mar; 295(10):3017-3028. PubMed ID: 31996378
[TBL] [Abstract][Full Text] [Related]
5. Targeting YAP and Hippo signaling pathway in liver cancer.
Liu AM; Xu MZ; Chen J; Poon RT; Luk JM
Expert Opin Ther Targets; 2010 Aug; 14(8):855-68. PubMed ID: 20545481
[TBL] [Abstract][Full Text] [Related]
6. The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression.
He C; Mao D; Hua G; Lv X; Chen X; Angeletti PC; Dong J; Remmenga SW; Rodabaugh KJ; Zhou J; Lambert PF; Yang P; Davis JS; Wang C
EMBO Mol Med; 2015 Nov; 7(11):1426-49. PubMed ID: 26417066
[TBL] [Abstract][Full Text] [Related]
7. Dual Role of a C-Terminally Truncated Isoform of Large Tumor Suppressor Kinase 1 in the Regulation of Hippo Signaling and Tissue Growth.
Matsui Y; Zhang Y; Paulson RF; Lai ZC
DNA Cell Biol; 2019 Jan; 38(1):91-106. PubMed ID: 30461308
[TBL] [Abstract][Full Text] [Related]
8. Hippo signaling dysfunction induces cancer cell addiction to YAP.
Han H; Yang B; Nakaoka HJ; Yang J; Zhao Y; Le Nguyen K; Bishara AT; Mandalia TK; Wang W
Oncogene; 2018 Dec; 37(50):6414-6424. PubMed ID: 30068939
[TBL] [Abstract][Full Text] [Related]
9. β-Catenin destruction complex-independent regulation of Hippo-YAP signaling by APC in intestinal tumorigenesis.
Cai J; Maitra A; Anders RA; Taketo MM; Pan D
Genes Dev; 2015 Jul; 29(14):1493-506. PubMed ID: 26193883
[TBL] [Abstract][Full Text] [Related]
10. Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway.
Ehmer U; Sage J
Mol Cancer Res; 2016 Feb; 14(2):127-40. PubMed ID: 26432795
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Hippo pathway: Clinical implications and therapeutics.
Ye S; Eisinger-Mathason TS
Pharmacol Res; 2016 Jan; 103():270-8. PubMed ID: 26678601
[TBL] [Abstract][Full Text] [Related]
12. An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2.
Park GS; Oh H; Kim M; Kim T; Johnson RL; Irvine KD; Lim DS
Oncotarget; 2016 Apr; 7(17):24063-75. PubMed ID: 27006470
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling.
Yu FX; Zhao B; Panupinthu N; Jewell JL; Lian I; Wang LH; Zhao J; Yuan H; Tumaneng K; Li H; Fu XD; Mills GB; Guan KL
Cell; 2012 Aug; 150(4):780-91. PubMed ID: 22863277
[TBL] [Abstract][Full Text] [Related]
14. The Hippo pathway member Nf2 is required for inner cell mass specification.
Cockburn K; Biechele S; Garner J; Rossant J
Curr Biol; 2013 Jul; 23(13):1195-201. PubMed ID: 23791728
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of the Hippo-YAP pathway in multiple cancer contexts.
Kim HB; Myung SJ
BMB Rep; 2018 Mar; 51(3):119-125. PubMed ID: 29366445
[TBL] [Abstract][Full Text] [Related]
16. Hippo signaling pathway is altered in Duchenne muscular dystrophy.
Vita GL; Polito F; Oteri R; Arrigo R; Ciranni AM; Musumeci O; Messina S; Rodolico C; Di Giorgio RM; Vita G; Aguennouz M
PLoS One; 2018; 13(10):e0205514. PubMed ID: 30304034
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between Hippo signalling and miRNAs in tumour progression.
Li N; Xie C; Lu N
FEBS J; 2017 Apr; 284(7):1045-1055. PubMed ID: 27973704
[TBL] [Abstract][Full Text] [Related]
18. TEAD1 mediates the oncogenic activities of Hippo-YAP1 signaling in osteosarcoma.
Chai J; Xu S; Guo F
Biochem Biophys Res Commun; 2017 Jun; 488(2):297-302. PubMed ID: 28483529
[TBL] [Abstract][Full Text] [Related]
19. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ.
Yi J; Lu L; Yanger K; Wang W; Sohn BH; Stanger BZ; Zhang M; Martin JF; Ajani JA; Chen J; Lee JS; Song S; Johnson RL
Hepatology; 2016 Nov; 64(5):1757-1772. PubMed ID: 27531557
[TBL] [Abstract][Full Text] [Related]
20. The complex entanglement of Hippo-Yap/Taz signaling in tumor immunity.
White SM; Murakami S; Yi C
Oncogene; 2019 Apr; 38(16):2899-2909. PubMed ID: 30617303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
